[
  {
    "ts": "2025-10-29T15:48:00+00:00",
    "headline": "GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View",
    "summary": "GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.",
    "url": "https://finance.yahoo.com/news/gsks-q3-earnings-sales-beat-154800513.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "e5b7fa8b-6d8a-3b00-a5d6-2f465d0b0393",
      "content": {
        "id": "e5b7fa8b-6d8a-3b00-a5d6-2f465d0b0393",
        "contentType": "STORY",
        "title": "GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View",
        "description": "",
        "summary": "GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.",
        "pubDate": "2025-10-29T15:48:00Z",
        "displayTime": "2025-10-29T15:48:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gsks-q3-earnings-sales-beat-154800513.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gsks-q3-earnings-sales-beat-154800513.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GSK.L"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-29T12:05:00+00:00",
    "headline": "Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which aims to affirm IMAAVY™ (nipocalimab-aahu) as the FcRn blocker of choice for appropriate gMG patients. The EPIC study design and Vibrance-MG Phase 2/3 long-term extension (LTE) data are among 38 abstracts the Company will present at the 2025 Myasthenia Gravis Foundation of America (MGFA) Scientific Session and the America",
    "url": "https://finance.yahoo.com/news/johnson-johnson-announces-first-head-120500884.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "ae06953a-0c82-3aa4-bdfa-215cfbfdd065",
      "content": {
        "id": "ae06953a-0c82-3aa4-bdfa-215cfbfdd065",
        "contentType": "STORY",
        "title": "Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting",
        "description": "",
        "summary": "Johnson & Johnson (NYSE: JNJ) today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which aims to affirm IMAAVY™ (nipocalimab-aahu) as the FcRn blocker of choice for appropriate gMG patients. The EPIC study design and Vibrance-MG Phase 2/3 long-term extension (LTE) data are among 38 abstracts the Company will present at the 2025 Myasthenia Gravis Foundation of America (MGFA) Scientific Session and the America",
        "pubDate": "2025-10-29T12:05:00Z",
        "displayTime": "2025-10-29T12:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
          "originalWidth": 400,
          "originalHeight": 37,
          "caption": "(PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qSZrWcbnRRL1JYTreG4GkQ--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b.cf.webp",
              "width": 400,
              "height": 37,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k.1EfOOwAn37l11cbOcgUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-announces-first-head-120500884.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-announces-first-head-120500884.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-29T01:42:28+00:00",
    "headline": "Freedom Capital Downgrades Johnson & Johnson (JNJ) to Hold Despite Strong Q3 Results",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the Best Dividend Stocks for the Best Retirement Portfolio. On October 22, Free⁠dom Capital Mark‍ets has lowered i⁠ts‍ rating on Johnson & Johnson (NYSE:JNJ) from B‍uy to Hold, even as it raised the stock’s price tar⁠get fro‌m $180 to $19​0 f⁠oll​owing a solid third-qua⁠rte​r⁠ perform⁠ance. The healt‌hcare company […]",
    "url": "https://finance.yahoo.com/news/freedom-capital-downgrades-johnson-johnson-014228921.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "f7a10d34-4eea-337a-9e6f-2852fcd4fab0",
      "content": {
        "id": "f7a10d34-4eea-337a-9e6f-2852fcd4fab0",
        "contentType": "STORY",
        "title": "Freedom Capital Downgrades Johnson & Johnson (JNJ) to Hold Despite Strong Q3 Results",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is included among the Best Dividend Stocks for the Best Retirement Portfolio. On October 22, Free⁠dom Capital Mark‍ets has lowered i⁠ts‍ rating on Johnson & Johnson (NYSE:JNJ) from B‍uy to Hold, even as it raised the stock’s price tar⁠get fro‌m $180 to $19​0 f⁠oll​owing a solid third-qua⁠rte​r⁠ perform⁠ance. The healt‌hcare company […]",
        "pubDate": "2025-10-29T01:42:28Z",
        "displayTime": "2025-10-29T01:42:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Freedom Capital Downgrades Johnson & Johnson (JNJ) to Hold Despite Strong Q3 Results",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qG_90ptmVmYmlFzMjoC0Yw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q3JcjOP_BI3o_9_ANEkK.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/freedom-capital-downgrades-johnson-johnson-014228921.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/freedom-capital-downgrades-johnson-johnson-014228921.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]